D&D Pharmatech
Financials
Valuation Metrics
D&D Pharmatech's Market Cap is ₩3.0T. At end of 2025 it was ₩4.2T. Ranked #157 of 2,436 in KR market (top 6%), #25 of 1,649 on KOSDAQ (top 2%), #16 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 7%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 2.97T KRW | KR#157/2,436 Sec#16/234 |
| Revenue | 3.01B KRW | KR#2,376/2,436 Sec#208/234 |
| Net Income | -24.01B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 92.50B KRW | KR#1,806/2,436 Sec#147/234 |
| Net Assets | 73.95B KRW | KR#1,609/2,436 Sec#135/234 |
| Employees | 24 | KR#2,206/2,436 Sec#205/234 |
| Value | ||
| P/B | 40.17x | KR#2,400/2,436 Sec#227/234 |
| P/S | 985.85x | KR#2,412/2,436 Sec#226/234 |
| FCF Yield | -0.71% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -32.47% | KR#2,186/2,436 Sec#178/234 |
| ROA | -25.96% | KR#2,263/2,436 Sec#187/234 |
| Op. Margin | -1188.29% | KR#2,389/2,436 Sec#217/234 |
| Revenue Growth | -90.89% | KR#2,340/2,436 Sec#210/234 |
| Financial Health | ||
| Debt Ratio | 125.08% | KR#765/2,436 Sec#91/234 |
| Total Debt | 2.54B KRW | KR#1,877/2,436 Sec#182/234 |
| FCF | -21.20B KRW | KR#1,912/2,436 Sec#182/234 |
| Cash | 24.57B KRW | KR#1,119/2,436 Sec#78/234 |
| Current Ratio | 8.02x | KR#144/2,436 Sec#36/234 |
| Performance | ||
| 1Y Return | 102.14% | KR#142/2,436 Sec#13/234 |
| 1M Return | -20.69% | KR#2,339/2,436 Sec#228/234 |
| From 52W High | -44.43% | KR#1,171/2,436 Sec#96/234 |
| 1Y MDD | -58.90% | KR#1,343/2,436 Sec#107/234 |
| Trading | ||
| Volume | 1,781,391 shares | KR#83/2,436 Sec#6/234 |
| Foreign Own. | 6.50% | KR#670/2,436 Sec#65/234 |
| Per Share | ||
| EPS | -535 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,702 KRW | KR#2,111/2,436 Sec#178/234 |
Company Info
D&D Pharmatech, established in 2014 and listed on KOSDAQ in 2024, holds subsidiaries such as Neuraly Inc., Valted Seq Inc., and P4 Microbiome Inc. The company researches and develops new drugs for metabolic, neurodegenerative, and fibrotic diseases using technologies like GLP-1, with a diverse pipeline including oral obesity treatments. Leveraging new drug development capabilities through drug delivery technology, it advances its business via technology transfer and co-development with global partners. D&D Pharmatech is headquartered in Seongnam-si, Gyeonggi-do.